Advertisement

Index by Author

October 1999; 48 (10)
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z

A

  1. Adachi, M

    • Rapid increase in circulating leptin in ventromedial hypothalamus-lesioned rats: role of hyperinsulinemia and implication for upregulation mechanism. Diabetes October 1999 48:2034-2038; doi:10.2337/diabetes.48.10.2034

  2. Aiello, L P

    • Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes October 1999 48:1899-1906; doi:10.2337/diabetes.48.10.1899

  3. Aizawa-Abe, M

    • Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes October 1999 48:2028-2033; doi:10.2337/diabetes.48.10.2028

  4. Alavi, N

    • Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes October 1999 48:2066-2073; doi:10.2337/diabetes.48.10.2066

  5. Andersen, R E

    • Tumor necrosis factor-alpha-238 and -308 polymorphisms do not associated with traits related to obesity and insulin resistance. Diabetes October 1999 48:2096-2098; doi:10.2337/diabetes.48.10.2096

  6. Andreu, E

    • Mechanisms of glucose hypersensitivity in beta-cells from normoglycemic, partially pancreatectomized mice. Diabetes October 1999 48:1954-1961; doi:10.2337/diabetes.48.10.1954

  7. Andrikopoulos, S

    • Two novel immortal pancreatic beta-cell lines expressing and secreting human islet amyloid polypeptide do not spontaneously develop islet amyloid. Diabetes October 1999 48:1962-1970; doi:10.2337/diabetes.48.10.1962

  8. Aniento, I

    • Palmitate and oleate induce the immediate-early response genes c-fos and nur-77 in the pancreatic beta-cell line INS-1. Diabetes October 1999 48:2007-2014; doi:10.2337/diabetes.48.10.2007

  9. Antonellis, A

    • Hepatocyte nuclear factor-4gamma: cDNA sequence, gene organization, and mutation screening in early-onset autosomal-dominant type 2 diabetes. Diabetes October 1999 48:2099-2102; doi:10.2337/diabetes.48.10.2099

  10. Avila, C

    • Acute modulation of albumin microvascular leakage by advanced glycation end products in microcirculation of diabetic rats in vivo. Diabetes October 1999 48:2052-2058; doi:10.2337/diabetes.48.10.2052

B

  1. Bach, J F

    • Identification of peptides from autoantigens GAD65 and IA-2 that bind to HLA class II molecules predisposing to or protecting from type 1 diabetes. Diabetes October 1999 48:1937-1947; doi:10.2337/diabetes.48.10.1937

  2. Bak, A

    • Tyrosine phosphorylation of specific protein kinase C isoenzymes participates in insulin stimulation of glucose transport in primary cultures of rat skeletal muscle. Diabetes October 1999 48:1922-1929; doi:10.2337/diabetes.48.10.1922

  3. Bennet, W

    • Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes October 1999 48:1907-1914; doi:10.2337/diabetes.48.10.1907

  4. Bertuzzi, F

    • Mechanisms of coordination of Ca2+ signals in pancreatic islet cells. Diabetes October 1999 48:1971-1978; doi:10.2337/diabetes.48.10.1971

  5. Bonnardel-Phu, E

    • Acute modulation of albumin microvascular leakage by advanced glycation end products in microcirculation of diabetic rats in vivo. Diabetes October 1999 48:2052-2058; doi:10.2337/diabetes.48.10.2052

  6. Borgschulze, M

    • Hepatocyte nuclear factor-4gamma: cDNA sequence, gene organization, and mutation screening in early-onset autosomal-dominant type 2 diabetes. Diabetes October 1999 48:2099-2102; doi:10.2337/diabetes.48.10.2099

  7. Braiman, L

    • Tyrosine phosphorylation of specific protein kinase C isoenzymes participates in insulin stimulation of glucose transport in primary cultures of rat skeletal muscle. Diabetes October 1999 48:1922-1929; doi:10.2337/diabetes.48.10.1922

  8. Brandhorst, D

    • Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes October 1999 48:1907-1914; doi:10.2337/diabetes.48.10.1907

  9. Brandhorst, H

    • Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes October 1999 48:1907-1914; doi:10.2337/diabetes.48.10.1907

  10. Brendel, M D

    • Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes October 1999 48:1907-1914; doi:10.2337/diabetes.48.10.1907

  11. Bretzel, R G

    • Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes October 1999 48:1907-1914; doi:10.2337/diabetes.48.10.1907

  12. Buteau, J

    • Palmitate and oleate induce the immediate-early response genes c-fos and nur-77 in the pancreatic beta-cell line INS-1. Diabetes October 1999 48:2007-2014; doi:10.2337/diabetes.48.10.2007

C

  1. Caillat-Zucman, S

    • Identification of peptides from autoantigens GAD65 and IA-2 that bind to HLA class II molecules predisposing to or protecting from type 1 diabetes. Diabetes October 1999 48:1937-1947; doi:10.2337/diabetes.48.10.1937

  2. Cartee, G D

    • Calorie restriction increases insulin-stimulated glucose transport in skeletal muscle from IRS-1 knockout mice. Diabetes October 1999 48:1930-1936; doi:10.2337/diabetes.48.10.1930

  3. Chaya, S

    • A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090

  4. Cheroutre, H

    • T-cell production of an inducible interleukin-10 transgene provides limited protection from autoimmune diabetes. Diabetes October 1999 48:1948-1953; doi:10.2337/diabetes.48.10.1948

  5. Cheskin, L J

    • Tumor necrosis factor-alpha-238 and -308 polymorphisms do not associated with traits related to obesity and insulin resistance. Diabetes October 1999 48:2096-2098; doi:10.2337/diabetes.48.10.2096

  6. Clerc, P

    • Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes October 1999 48:2015-2021; doi:10.2337/diabetes.48.10.2015

  7. Codazzi, F

    • Mechanisms of coordination of Ca2+ signals in pancreatic islet cells. Diabetes October 1999 48:1971-1978; doi:10.2337/diabetes.48.10.1971

  8. Corominola, H

    • Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes October 1999 48:2015-2021; doi:10.2337/diabetes.48.10.2015

  9. Craven, P A

    • Regulation of the laminin C1 promoter in cultured mesangial cells. Diabetes October 1999 48:2083-2089; doi:10.2337/diabetes.48.10.2083

D

  1. Davalli, A M

    • Mechanisms of coordination of Ca2+ signals in pancreatic islet cells. Diabetes October 1999 48:1971-1978; doi:10.2337/diabetes.48.10.1971

  2. Davidoff, A J

    • Metformin but not glyburide prevents high glucose-induced abnormalities in relaxation and intracellular Ca2+ transients in adult rat ventricular myocytes. Diabetes October 1999 48:2059-2065; doi:10.2337/diabetes.48.10.2059

  3. Delmeire, D

    • Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes October 1999 48:1979-1986; doi:10.2337/diabetes.48.10.1979

  4. DeRubertis, F R

    • Regulation of the laminin C1 promoter in cultured mesangial cells. Diabetes October 1999 48:2083-2089; doi:10.2337/diabetes.48.10.2083

  5. Di Carlo, V

    • Mechanisms of coordination of Ca2+ signals in pancreatic islet cells. Diabetes October 1999 48:1971-1978; doi:10.2337/diabetes.48.10.1971

  6. Dominguez, L J

    • Metformin but not glyburide prevents high glucose-induced abnormalities in relaxation and intracellular Ca2+ transients in adult rat ventricular myocytes. Diabetes October 1999 48:2059-2065; doi:10.2337/diabetes.48.10.2059

  7. Doria, A

    • Hepatocyte nuclear factor-4gamma: cDNA sequence, gene organization, and mutation screening in early-onset autosomal-dominant type 2 diabetes. Diabetes October 1999 48:2099-2102; doi:10.2337/diabetes.48.10.2099

  8. Drucker, D J

    • Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes October 1999 48:1979-1986; doi:10.2337/diabetes.48.10.1979

  9. Dufresne, M

    • Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes October 1999 48:2015-2021; doi:10.2337/diabetes.48.10.2015

  10. Duh, E

    • Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes October 1999 48:1899-1906; doi:10.2337/diabetes.48.10.1899

  11. Dumke, C L

    • Calorie restriction increases insulin-stimulated glucose transport in skeletal muscle from IRS-1 knockout mice. Diabetes October 1999 48:1930-1936; doi:10.2337/diabetes.48.10.1930

E

  1. Ebihara, K

    • Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes October 1999 48:2028-2033; doi:10.2337/diabetes.48.10.2028

  2. Elgue, G

    • Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes October 1999 48:1907-1914; doi:10.2337/diabetes.48.10.1907

  3. Escrieut, C

    • Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes October 1999 48:2015-2021; doi:10.2337/diabetes.48.10.2015

F

  1. Fesce, R

    • Mechanisms of coordination of Ca2+ signals in pancreatic islet cells. Diabetes October 1999 48:1971-1978; doi:10.2337/diabetes.48.10.1971

  2. Flamez, D

    • Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes October 1999 48:1979-1986; doi:10.2337/diabetes.48.10.1979

  3. Fourmy, D

    • Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes October 1999 48:2015-2021; doi:10.2337/diabetes.48.10.2015

  4. Fujimoto, W Y

    • Two novel immortal pancreatic beta-cell lines expressing and secreting human islet amyloid polypeptide do not spontaneously develop islet amyloid. Diabetes October 1999 48:1962-1970; doi:10.2337/diabetes.48.10.1962

G

  1. Gazdag, A C

    • Calorie restriction increases insulin-stimulated glucose transport in skeletal muscle from IRS-1 knockout mice. Diabetes October 1999 48:1930-1936; doi:10.2337/diabetes.48.10.1930

  2. Gilon, P

    • Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes October 1999 48:1979-1986; doi:10.2337/diabetes.48.10.1979

  3. Gleason, C E

    • In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression. Diabetes October 1999 48:1995-2000; doi:10.2337/diabetes.48.10.1995

  4. Gomis, R

    • Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes October 1999 48:2015-2021; doi:10.2337/diabetes.48.10.2015

  5. Gonoi, T

    • Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes October 1999 48:2001-2006; doi:10.2337/diabetes.48.10.2001

  6. Grohovaz, F

    • Mechanisms of coordination of Ca2+ signals in pancreatic islet cells. Diabetes October 1999 48:1971-1978; doi:10.2337/diabetes.48.10.1971

  7. Groth, C G

    • Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes October 1999 48:1907-1914; doi:10.2337/diabetes.48.10.1907

  8. Guy-Crotte, O

    • Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes October 1999 48:2015-2021; doi:10.2337/diabetes.48.10.2015

H

  1. Hagenbaugh, A

    • T-cell production of an inducible interleukin-10 transgene provides limited protection from autoimmune diabetes. Diabetes October 1999 48:1948-1953; doi:10.2337/diabetes.48.10.1948

  2. Hamada, Y

    • A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090

  3. Harfouch-Hammoud, E

    • Identification of peptides from autoantigens GAD65 and IA-2 that bind to HLA class II molecules predisposing to or protecting from type 1 diabetes. Diabetes October 1999 48:1937-1947; doi:10.2337/diabetes.48.10.1937

  4. Harmon, J S

    • In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression. Diabetes October 1999 48:1995-2000; doi:10.2337/diabetes.48.10.1995

  5. Hasselbalch, S G

    • No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes October 1999 48:1915-1921; doi:10.2337/diabetes.48.10.1915

  6. Hayase, M

    • Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes October 1999 48:2028-2033; doi:10.2337/diabetes.48.10.2028

  7. Henquin, J C

    • Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes October 1999 48:1979-1986; doi:10.2337/diabetes.48.10.1979

  8. Hirano, T

    • Rapid increase in circulating leptin in ventromedial hypothalamus-lesioned rats: role of hyperinsulinemia and implication for upregulation mechanism. Diabetes October 1999 48:2034-2038; doi:10.2337/diabetes.48.10.2034

  9. Holm, S

    • No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes October 1999 48:1915-1921; doi:10.2337/diabetes.48.10.1915

  10. Hong, C P

    • Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes October 1999 48:2039-2044; doi:10.2337/diabetes.48.10.2039

  11. Hotamisligil, G S

    • Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes October 1999 48:1987-1994; doi:10.2337/diabetes.48.10.1987

  12. Hotta, N

    • A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090

  13. Howell, W M

    • Two novel immortal pancreatic beta-cell lines expressing and secreting human islet amyloid polypeptide do not spontaneously develop islet amyloid. Diabetes October 1999 48:1962-1970; doi:10.2337/diabetes.48.10.1962

  14. Hunter-Berger, K K

    • In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression. Diabetes October 1999 48:1995-2000; doi:10.2337/diabetes.48.10.1995

I

  1. Ienaga, K

    • A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090

  2. Inoue, S

    • Rapid increase in circulating leptin in ventromedial hypothalamus-lesioned rats: role of hyperinsulinemia and implication for upregulation mechanism. Diabetes October 1999 48:2034-2038; doi:10.2337/diabetes.48.10.2034

  3. Iwanaga, T

    • Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes October 1999 48:2001-2006; doi:10.2337/diabetes.48.10.2001

J

  1. Jacobs, D R, Jr

    • Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes October 1999 48:2039-2044; doi:10.2337/diabetes.48.10.2039

  2. Jung, G

    • Identification of peptides from autoantigens GAD65 and IA-2 that bind to HLA class II molecules predisposing to or protecting from type 1 diabetes. Diabetes October 1999 48:1937-1947; doi:10.2337/diabetes.48.10.1937

K

  1. Kageyama, H

    • Rapid increase in circulating leptin in ventromedial hypothalamus-lesioned rats: role of hyperinsulinemia and implication for upregulation mechanism. Diabetes October 1999 48:2034-2038; doi:10.2337/diabetes.48.10.2034

  2. Kahn, C R

    • Calorie restriction increases insulin-stimulated glucose transport in skeletal muscle from IRS-1 knockout mice. Diabetes October 1999 48:1930-1936; doi:10.2337/diabetes.48.10.1930

  3. Kahn, S E

    • Two novel immortal pancreatic beta-cell lines expressing and secreting human islet amyloid polypeptide do not spontaneously develop islet amyloid. Diabetes October 1999 48:1962-1970; doi:10.2337/diabetes.48.10.1962

  4. Kamiya, H

    • A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090

  5. Kashiba, M

    • Rapid increase in circulating leptin in ventromedial hypothalamus-lesioned rats: role of hyperinsulinemia and implication for upregulation mechanism. Diabetes October 1999 48:2034-2038; doi:10.2337/diabetes.48.10.2034

  6. Kasuga, M

    • Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of advanced glycation end products. Diabetes October 1999 48:2074-2082; doi:10.2337/diabetes.48.10.2074

  7. Kasuya, Y

    • A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090

  8. Kato, K

    • A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090

  9. Katsuura, G

    • Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes October 1999 48:2028-2033; doi:10.2337/diabetes.48.10.2028

  10. Kawaki, J

    • Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes October 1999 48:2001-2006; doi:10.2337/diabetes.48.10.2001

  11. Kishi, Y

    • Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy. Diabetes October 1999 48:2045-2051; doi:10.2337/diabetes.48.10.2045

  12. Knudsen, G M

    • No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes October 1999 48:1915-1921; doi:10.2337/diabetes.48.10.1915

  13. Koh, N

    • A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090

  14. Kojima, H

    • Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of advanced glycation end products. Diabetes October 1999 48:2074-2082; doi:10.2337/diabetes.48.10.2074

  15. Korsgren, O

    • Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes October 1999 48:1907-1914; doi:10.2337/diabetes.48.10.1907

  16. Krolewski, A S

    • Hepatocyte nuclear factor-4gamma: cDNA sequence, gene organization, and mutation screening in early-onset autosomal-dominant type 2 diabetes. Diabetes October 1999 48:2099-2102; doi:10.2337/diabetes.48.10.2099

  17. Kusunoki, H

    • Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of advanced glycation end products. Diabetes October 1999 48:2074-2082; doi:10.2337/diabetes.48.10.2074

L

  1. Larsson, R

    • Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes October 1999 48:1907-1914; doi:10.2337/diabetes.48.10.1907

  2. Leehey, D J

    • Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes October 1999 48:2066-2073; doi:10.2337/diabetes.48.10.2066

  3. Lehman, D L

    • Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia. Diabetes October 1999 48:2022-2027; doi:10.2337/diabetes.48.10.2022

  4. Liu, B F

    • Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of advanced glycation end products. Diabetes October 1999 48:2074-2082; doi:10.2337/diabetes.48.10.2074

  5. Lo, D

    • T-cell production of an inducible interleukin-10 transgene provides limited protection from autoimmune diabetes. Diabetes October 1999 48:1948-1953; doi:10.2337/diabetes.48.10.1948

  6. Low, P A

    • Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy. Diabetes October 1999 48:2045-2051; doi:10.2337/diabetes.48.10.2045

  7. Luepker, R

    • Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes October 1999 48:2039-2044; doi:10.2337/diabetes.48.10.2039

M

  1. Makowski, L

    • Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes October 1999 48:1987-1994; doi:10.2337/diabetes.48.10.1987

  2. Martín, F

    • Mechanisms of glucose hypersensitivity in beta-cells from normoglycemic, partially pancreatectomized mice. Diabetes October 1999 48:1954-1961; doi:10.2337/diabetes.48.10.1954

  3. Masuzaki, H

    • Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes October 1999 48:2028-2033; doi:10.2337/diabetes.48.10.2028

  4. Matsuoka, N

    • Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes October 1999 48:2028-2033; doi:10.2337/diabetes.48.10.2028

  5. Meyers, D S

    • Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes October 1999 48:1987-1994; doi:10.2337/diabetes.48.10.1987

  6. Miki, T

    • Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes October 1999 48:2001-2006; doi:10.2337/diabetes.48.10.2001

  7. Mitsuhashi, N

    • Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes October 1999 48:2001-2006; doi:10.2337/diabetes.48.10.2001

  8. Miura, M

    • Rapid increase in circulating leptin in ventromedial hypothalamus-lesioned rats: role of hyperinsulinemia and implication for upregulation mechanism. Diabetes October 1999 48:2034-2038; doi:10.2337/diabetes.48.10.2034

  9. Miwa, K

    • A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090

  10. Miyata, S

    • Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of advanced glycation end products. Diabetes October 1999 48:2074-2082; doi:10.2337/diabetes.48.10.2074

  11. Miyazaki, M

    • Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes October 1999 48:2001-2006; doi:10.2337/diabetes.48.10.2001

  12. Mizubayashi, R

    • A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090

  13. Moens, K

    • Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes October 1999 48:1979-1986; doi:10.2337/diabetes.48.10.1979

  14. Montanya, E

    • Mechanisms of glucose hypersensitivity in beta-cells from normoglycemic, partially pancreatectomized mice. Diabetes October 1999 48:1954-1961; doi:10.2337/diabetes.48.10.1954

  15. Moran, A

    • Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes October 1999 48:2039-2044; doi:10.2337/diabetes.48.10.2039

  16. Morgan, M

    • Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes October 1999 48:1987-1994; doi:10.2337/diabetes.48.10.1987

  17. Moriscot, C

    • Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes October 1999 48:2015-2021; doi:10.2337/diabetes.48.10.2015

N

  1. Nagashima, K

    • Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes October 1999 48:2001-2006; doi:10.2337/diabetes.48.10.2001

  2. Nakajima, N

    • Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes October 1999 48:2001-2006; doi:10.2337/diabetes.48.10.2001

  3. Nakamura, J

    • A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090

  4. Nakao, K

    • Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes October 1999 48:2028-2033; doi:10.2337/diabetes.48.10.2028

  5. Nakashima, E

    • A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090

  6. Nakayama, M

    • A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090

  7. Namba, Y

    • Rapid increase in circulating leptin in ventromedial hypothalamus-lesioned rats: role of hyperinsulinemia and implication for upregulation mechanism. Diabetes October 1999 48:2034-2038; doi:10.2337/diabetes.48.10.2034

  8. Nano, R

    • Mechanisms of coordination of Ca2+ signals in pancreatic islet cells. Diabetes October 1999 48:1971-1978; doi:10.2337/diabetes.48.10.1971

  9. Naruse, K

    • A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090

  10. Neal, H

    • T-cell production of an inducible interleukin-10 transgene provides limited protection from autoimmune diabetes. Diabetes October 1999 48:1948-1953; doi:10.2337/diabetes.48.10.1948

  11. Newgard, C B

    • Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia. Diabetes October 1999 48:2022-2027; doi:10.2337/diabetes.48.10.2022

  12. Nickander, K K

    • Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy. Diabetes October 1999 48:2045-2051; doi:10.2337/diabetes.48.10.2045

  13. Nilsson, B

    • Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes October 1999 48:1907-1914; doi:10.2337/diabetes.48.10.1907

  14. Numata, Y

    • Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes October 1999 48:2028-2033; doi:10.2337/diabetes.48.10.2028

O

  1. O'Doherty, R M

    • Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia. Diabetes October 1999 48:2022-2027; doi:10.2337/diabetes.48.10.2022

  2. Ogawa, Y

    • Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes October 1999 48:2028-2033; doi:10.2337/diabetes.48.10.2028

  3. Oka, J

    • Rapid increase in circulating leptin in ventromedial hypothalamus-lesioned rats: role of hyperinsulinemia and implication for upregulation mechanism. Diabetes October 1999 48:2034-2038; doi:10.2337/diabetes.48.10.2034

  4. Osaka, T

    • Rapid increase in circulating leptin in ventromedial hypothalamus-lesioned rats: role of hyperinsulinemia and implication for upregulation mechanism. Diabetes October 1999 48:2034-2038; doi:10.2337/diabetes.48.10.2034

  5. Oseid, E A

    • In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression. Diabetes October 1999 48:1995-2000; doi:10.2337/diabetes.48.10.1995

  6. Otto, H

    • Identification of peptides from autoantigens GAD65 and IA-2 that bind to HLA class II molecules predisposing to or protecting from type 1 diabetes. Diabetes October 1999 48:1937-1947; doi:10.2337/diabetes.48.10.1937

P

  1. Parker, R A

    • Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes October 1999 48:1987-1994; doi:10.2337/diabetes.48.10.1987

  2. Paulson, O B

    • No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes October 1999 48:1915-1921; doi:10.2337/diabetes.48.10.1915

  3. Pauza, M E

    • T-cell production of an inducible interleukin-10 transgene provides limited protection from autoimmune diabetes. Diabetes October 1999 48:1948-1953; doi:10.2337/diabetes.48.10.1948

  4. Pertusa, J A

    • Mechanisms of glucose hypersensitivity in beta-cells from normoglycemic, partially pancreatectomized mice. Diabetes October 1999 48:1954-1961; doi:10.2337/diabetes.48.10.1954

  5. Phillips, S L

    • Regulation of the laminin C1 promoter in cultured mesangial cells. Diabetes October 1999 48:2083-2089; doi:10.2337/diabetes.48.10.2083

  6. Pinborg, L H

    • No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes October 1999 48:1915-1921; doi:10.2337/diabetes.48.10.1915

  7. Plengvidhya, N

    • Hepatocyte nuclear factor-4gamma: cDNA sequence, gene organization, and mutation screening in early-onset autosomal-dominant type 2 diabetes. Diabetes October 1999 48:2099-2102; doi:10.2337/diabetes.48.10.2099

  8. Poleev, A

    • Hepatocyte nuclear factor-4gamma: cDNA sequence, gene organization, and mutation screening in early-onset autosomal-dominant type 2 diabetes. Diabetes October 1999 48:2099-2102; doi:10.2337/diabetes.48.10.2099

  9. Pozza, G

    • Mechanisms of coordination of Ca2+ signals in pancreatic islet cells. Diabetes October 1999 48:1971-1978; doi:10.2337/diabetes.48.10.1971

  10. Prentki, M

    • Palmitate and oleate induce the immediate-early response genes c-fos and nur-77 in the pancreatic beta-cell line INS-1. Diabetes October 1999 48:2007-2014; doi:10.2337/diabetes.48.10.2007

  11. Prineas, R

    • Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes October 1999 48:2039-2044; doi:10.2337/diabetes.48.10.2039

R

  1. Raurell, M

    • Mechanisms of glucose hypersensitivity in beta-cells from normoglycemic, partially pancreatectomized mice. Diabetes October 1999 48:1954-1961; doi:10.2337/diabetes.48.10.1954

  2. Reig, J A

    • Palmitate and oleate induce the immediate-early response genes c-fos and nur-77 in the pancreatic beta-cell line INS-1. Diabetes October 1999 48:2007-2014; doi:10.2337/diabetes.48.10.2007

  3. Ren, J

    • Metformin but not glyburide prevents high glucose-induced abnormalities in relaxation and intracellular Ca2+ transients in adult rat ventricular myocytes. Diabetes October 1999 48:2059-2065; doi:10.2337/diabetes.48.10.2059

  4. Ripoll, C

    • Mechanisms of glucose hypersensitivity in beta-cells from normoglycemic, partially pancreatectomized mice. Diabetes October 1999 48:1954-1961; doi:10.2337/diabetes.48.10.1954

  5. Robertson, R P

    • In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression. Diabetes October 1999 48:1995-2000; doi:10.2337/diabetes.48.10.1995

  6. Roche, E

    • Palmitate and oleate induce the immediate-early response genes c-fos and nur-77 in the pancreatic beta-cell line INS-1. Diabetes October 1999 48:2007-2014; doi:10.2337/diabetes.48.10.2007

  7. Rovira, J M

    • Mechanisms of glucose hypersensitivity in beta-cells from normoglycemic, partially pancreatectomized mice. Diabetes October 1999 48:1954-1961; doi:10.2337/diabetes.48.10.1954

  8. Ryffel, G U

    • Hepatocyte nuclear factor-4gamma: cDNA sequence, gene organization, and mutation screening in early-onset autosomal-dominant type 2 diabetes. Diabetes October 1999 48:2099-2102; doi:10.2337/diabetes.48.10.2099

S

  1. Saillan-Barreau, C

    • Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes October 1999 48:2015-2021; doi:10.2337/diabetes.48.10.2015

  2. Sakakibara, F

    • A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090

  3. Sampson, S R

    • Tyrosine phosphorylation of specific protein kinase C isoenzymes participates in insulin stimulation of glucose transport in primary cultures of rat skeletal muscle. Diabetes October 1999 48:1922-1929; doi:10.2337/diabetes.48.10.1922

  4. Sanchez-Andrés, J V

    • Mechanisms of glucose hypersensitivity in beta-cells from normoglycemic, partially pancreatectomized mice. Diabetes October 1999 48:1954-1961; doi:10.2337/diabetes.48.10.1954

  5. Sanchez, D

    • Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes October 1999 48:2015-2021; doi:10.2337/diabetes.48.10.2015

  6. Satoh, N

    • Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes October 1999 48:2028-2033; doi:10.2337/diabetes.48.10.2028

  7. Scheja, L

    • Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes October 1999 48:1987-1994; doi:10.2337/diabetes.48.10.1987

  8. Schmelzer, J D

    • Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy. Diabetes October 1999 48:2045-2051; doi:10.2337/diabetes.48.10.2045

  9. Schmidt, A M

    • Acute modulation of albumin microvascular leakage by advanced glycation end products in microcirculation of diabetic rats in vivo. Diabetes October 1999 48:2052-2058; doi:10.2337/diabetes.48.10.2052

  10. Schmidt, J F

    • No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes October 1999 48:1915-1921; doi:10.2337/diabetes.48.10.1915

  11. Schuit, F

    • Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes October 1999 48:1979-1986; doi:10.2337/diabetes.48.10.1979

  12. Scrocchi, L A

    • Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes October 1999 48:1979-1986; doi:10.2337/diabetes.48.10.1979

  13. Seibert, M

    • Tumor necrosis factor-alpha-238 and -308 polymorphisms do not associated with traits related to obesity and insulin resistance. Diabetes October 1999 48:2096-2098; doi:10.2337/diabetes.48.10.2096

  14. Seino, S

    • Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes October 1999 48:2001-2006; doi:10.2337/diabetes.48.10.2001

  15. Sheffi-Friedman, L

    • Tyrosine phosphorylation of specific protein kinase C isoenzymes participates in insulin stimulation of glucose transport in primary cultures of rat skeletal muscle. Diabetes October 1999 48:1922-1929; doi:10.2337/diabetes.48.10.1922

  16. Shimshek, D R

    • Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes October 1999 48:1987-1994; doi:10.2337/diabetes.48.10.1987

  17. Sinaiko, A R

    • Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes October 1999 48:2039-2044; doi:10.2337/diabetes.48.10.2039

  18. Singh, A K

    • Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes October 1999 48:2066-2073; doi:10.2337/diabetes.48.10.2066

  19. Singh, R

    • Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes October 1999 48:2066-2073; doi:10.2337/diabetes.48.10.2066

  20. Socci, C

    • Mechanisms of coordination of Ca2+ signals in pancreatic islet cells. Diabetes October 1999 48:1971-1978; doi:10.2337/diabetes.48.10.1971

  21. Soria, B

    • Mechanisms of glucose hypersensitivity in beta-cells from normoglycemic, partially pancreatectomized mice. Diabetes October 1999 48:1954-1961; doi:10.2337/diabetes.48.10.1954
    • Palmitate and oleate induce the immediate-early response genes c-fos and nur-77 in the pancreatic beta-cell line INS-1. Diabetes October 1999 48:2007-2014; doi:10.2337/diabetes.48.10.2007

  22. Sowers, J R

    • Metformin but not glyburide prevents high glucose-induced abnormalities in relaxation and intracellular Ca2+ transients in adult rat ventricular myocytes. Diabetes October 1999 48:2059-2065; doi:10.2337/diabetes.48.10.2059

  23. Steinberger, J

    • Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes October 1999 48:2039-2044; doi:10.2337/diabetes.48.10.2039

  24. Suga, A

    • Rapid increase in circulating leptin in ventromedial hypothalamus-lesioned rats: role of hyperinsulinemia and implication for upregulation mechanism. Diabetes October 1999 48:2034-2038; doi:10.2337/diabetes.48.10.2034

  25. Sundberg, B

    • Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes October 1999 48:1907-1914; doi:10.2337/diabetes.48.10.1907

  26. Suzuki, K

    • Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of advanced glycation end products. Diabetes October 1999 48:2074-2082; doi:10.2337/diabetes.48.10.2074

T

  1. Tamaki, M

    • Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes October 1999 48:2028-2033; doi:10.2337/diabetes.48.10.2028

  2. Tanaka, J

    • Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes October 1999 48:2001-2006; doi:10.2337/diabetes.48.10.2001

  3. Tanaka, Y

    • In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression. Diabetes October 1999 48:1995-2000; doi:10.2337/diabetes.48.10.1995

  4. Tarasova, N

    • Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes October 1999 48:2015-2021; doi:10.2337/diabetes.48.10.2015

  5. Teague, J C

    • Two novel immortal pancreatic beta-cell lines expressing and secreting human islet amyloid polypeptide do not spontaneously develop islet amyloid. Diabetes October 1999 48:1962-1970; doi:10.2337/diabetes.48.10.1962

  6. Télémaque-Potts, S

    • Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia. Diabetes October 1999 48:2022-2027; doi:10.2337/diabetes.48.10.2022

  7. Tennenbaum, T

    • Tyrosine phosphorylation of specific protein kinase C isoenzymes participates in insulin stimulation of glucose transport in primary cultures of rat skeletal muscle. Diabetes October 1999 48:1922-1929; doi:10.2337/diabetes.48.10.1922

  8. Tritschler, H J

    • Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy. Diabetes October 1999 48:2045-2051; doi:10.2337/diabetes.48.10.2045

  9. Tsuji, M

    • Rapid increase in circulating leptin in ventromedial hypothalamus-lesioned rats: role of hyperinsulinemia and implication for upregulation mechanism. Diabetes October 1999 48:2034-2038; doi:10.2337/diabetes.48.10.2034

U

  1. Uriuhara, A

    • Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of advanced glycation end products. Diabetes October 1999 48:2074-2082; doi:10.2337/diabetes.48.10.2074

  2. Uysal, K T

    • Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes October 1999 48:1987-1994; doi:10.2337/diabetes.48.10.1987

V

  1. Van Breusegem, A

    • Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes October 1999 48:1979-1986; doi:10.2337/diabetes.48.10.1979

  2. van Endert, P M

    • Identification of peptides from autoantigens GAD65 and IA-2 that bind to HLA class II molecules predisposing to or protecting from type 1 diabetes. Diabetes October 1999 48:1937-1947; doi:10.2337/diabetes.48.10.1937

  3. Vaysse, N

    • Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes October 1999 48:2015-2021; doi:10.2337/diabetes.48.10.2015

  4. Verchere, C B

    • Two novel immortal pancreatic beta-cell lines expressing and secreting human islet amyloid polypeptide do not spontaneously develop islet amyloid. Diabetes October 1999 48:1962-1970; doi:10.2337/diabetes.48.10.1962

  5. Vicaut, E

    • Acute modulation of albumin microvascular leakage by advanced glycation end products in microcirculation of diabetic rats in vivo. Diabetes October 1999 48:2052-2058; doi:10.2337/diabetes.48.10.2052

  6. Videbaek, C

    • No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes October 1999 48:1915-1921; doi:10.2337/diabetes.48.10.1915

W

  1. Walk, T

    • Identification of peptides from autoantigens GAD65 and IA-2 that bind to HLA class II molecules predisposing to or protecting from type 1 diabetes. Diabetes October 1999 48:1937-1947; doi:10.2337/diabetes.48.10.1937

  2. Walston, J

    • Tumor necrosis factor-alpha-238 and -308 polymorphisms do not associated with traits related to obesity and insulin resistance. Diabetes October 1999 48:2096-2098; doi:10.2337/diabetes.48.10.2096

  3. Warram, J H

    • Hepatocyte nuclear factor-4gamma: cDNA sequence, gene organization, and mutation screening in early-onset autosomal-dominant type 2 diabetes. Diabetes October 1999 48:2099-2102; doi:10.2337/diabetes.48.10.2099

  4. Wautier, J L

    • Acute modulation of albumin microvascular leakage by advanced glycation end products in microcirculation of diabetic rats in vivo. Diabetes October 1999 48:2052-2058; doi:10.2337/diabetes.48.10.2052

  5. Wiesbrock, S M

    • Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes October 1999 48:1987-1994; doi:10.2337/diabetes.48.10.1987

  6. Wight, T N

    • Two novel immortal pancreatic beta-cell lines expressing and secreting human islet amyloid polypeptide do not spontaneously develop islet amyloid. Diabetes October 1999 48:1962-1970; doi:10.2337/diabetes.48.10.1962

  7. Wogan, L T

    • Hepatocyte nuclear factor-4gamma: cDNA sequence, gene organization, and mutation screening in early-onset autosomal-dominant type 2 diabetes. Diabetes October 1999 48:2099-2102; doi:10.2337/diabetes.48.10.2099

Y

  1. Yano, H

    • Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes October 1999 48:2001-2006; doi:10.2337/diabetes.48.10.2001

  2. Yao, J K

    • Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy. Diabetes October 1999 48:2045-2051; doi:10.2337/diabetes.48.10.2045

  3. Yasuda, Y

    • A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes October 1999 48:2090-2095; doi:10.2337/diabetes.48.10.2090

  4. Yen, C J

    • Tumor necrosis factor-alpha-238 and -308 polymorphisms do not associated with traits related to obesity and insulin resistance. Diabetes October 1999 48:2096-2098; doi:10.2337/diabetes.48.10.2096

  5. Yoshimasa, Y

    • Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes October 1999 48:2028-2033; doi:10.2337/diabetes.48.10.2028

  6. Yoshioka, T

    • Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes October 1999 48:2028-2033; doi:10.2337/diabetes.48.10.2028

Z

  1. Zollman, P J

    • Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy. Diabetes October 1999 48:2045-2051; doi:10.2337/diabetes.48.10.2045

Current Issue

  1. February 2012, 61 (2)
  1. Current Issue
  1. Alert me to new issues of Diabetes
Advertisement